Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis

Mohssen Elalfy^*, Yasser A. Wali, Mohamad Qari, Ghazi Al Damanhouri, Youssef Al-Tonbary, Dilek Yazman, Zakaria Al Hawsawi, Zeynep Karakas, Yurdanur Kilinc, M. Akif Yesilipek, Mohamed Badr, Usama Elsafy, Mostafa Salama, Yousryeia Abdel Rahman, Shebl Shebl, Anne Stilman, Noemi Toiber Temin, Fernando Tricta